ArticleMolecular biology reports2025
MALAT1 SNP (rs619586) shows a protective effect against type 1 diabetes mellitus, while the miR-146a SNP (rs57095329) is linked to an increased risk of developing the disease.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Decoding miRNA‑146a: Mechanisms of action in cardiovascular diseases and endocrine metabolic disorders (Review).International journal of molecular medicine · 2026Review
- Insights into the genetic aetiology of diabetes in Africa.EBioMedicine · 2026Review
- Artificial intelligence-driven therapeutics for disease modification in type 1 diabetes: a digital public health and clinical translation framework.Frontiers in public health · 2026Review
- Associations of MALAT1 rs619586/rs3200401 and ANRIL rs10965215/rs10738605 polymorphisms with type 2 diabetes and diabetic nephropathy risk in an Egyptian population.Frontiers in endocrinology · 2026Article
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
- Genetic association of microRNA-146a polymorphisms with the severity of coronary artery lesions in acute myocardial infarction.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 1 diabetes mellitus (T1DM), one of the most distinct and intricate metabolic diseases, is characterized by the death of pancreatic β-cells, which leads to a lack of insulin secretion and, ultimately, hyperglycemia. The condition is more common in children and adolescents. Long non-coding RNAs (LncRNAs) and microRNAs (miRNAs) regulate gene expression at the post-transcriptional level. They are essential to the control of several vital physiological processes. Many diseases have been linked to genetic variations in LncRNAs and miRNAs, though, their significance in type 1 diabetes mellitus (T1DM) is yet underappreciated.
methodsNinety-two Egyptian children diagnosed with T1DM as well as 92 healthy age- and sex-matched subjects were incorporated in the current research. Real-time polymerase chain reaction (RT-PCR) was used to assess rs619586 and rs57095329 in the study subjects.
resultsThe GG and AG genotypes and the G allele of MALAT1 (rs619586) were associated with a significant decrease in the risk of T1DM.Also, the AG and GG genotypes as well as the G allele of miR-146a (rs57095329) were associated with a significant increase in the risk of T1DM (p > 0.05, each).
conclusionFor the first time, our investigation had shown the connection between MALAT1 (rs619586) and miRNA-146a (rs57095329) polymorphisms and the risk of development of T1DM in Egyptians.
Indexed as
Identifiers
40138023What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.